Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  E-Therapeutics plc    ETX   GB00B2823H99

E-THERAPEUTICS PLC

(ETX)
  Report  
Delayed Quote. Delayed London Stock Exchange - 07/18 03:30:09 am
3.175 GBp   -0.78%
06/14Suspended Woodford fund has sold around £100 million of assets
RE
02/28E-THERAPEUTICS PLC : annual earnings release
2018E THERAPEUTICS : Research Collaboration Agreement with Novo Nordisk
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

e-Therapeutics plc : ETS6103 starts phase IIb trial for depression

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/31/2013 | 03:27am EDT
e-Therapeutics starts phase IIb trial of ETS6103 in major depressive disorder Oxford and Newcastle, UK, 31 October 2013 - e-Therapeutics plc (AIM: ETX) announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder. The trial is evaluating ETS6103 as a second- line treatment for patients who have not responded adequately to first-line therapy with an SSRI (selective serotonin reuptake inhibitor). It is being conducted by a group of primary care centres with a history of involvement in depression studies in the Glasgow area of Scotland.

Under the trial protocol, patients are enrolled prior to first-line treatment so that this can be standardised: every patient will receive the SSRI citalopram. Those with significant depressive symptoms remaining after six weeks on citalopram will enter the randomised phase of the study, which compares two different doses of ETS6103 with amitriptyline, a widely available tricyclic antidepressant. Approximately 160 patients will be randomised.
The principal objective is to test whether the two ETS6103 regimens have antidepressant activity 'non-inferior' to that of amitriptyline. The primary measure of activity is the change in Montgomery-Åsberg Depression Rating Scale (MADRS) score between randomisation and the end of treatment eight weeks later. Safety and a variety of secondary efficacy variables will also be assessed. e-Therapeutics expects to report the results of the trial in the first half of 2015. If these are positive, the Company intends to seek a licensing deal for the drug.
Stephen Self, Development Director at e-Therapeutics, said: "A clear need exists for better treatments for patients who do not respond well to first-line anti-depressant therapies. We believe that ETS6103 has potential in this population and are working with an experienced group of clinicians to test this proposition in a randomised controlled trial."

Contacts: e-Therapeutics plc

Malcolm Young / Daniel Elger Tel: +44 (0) 7909 915 068 www.etherapeutics.co.uk

Panmure Gordon (UK) Limited

Fred Walsh / Grishma Patel / Duncan Monteith
Tel: +44 (0) 20 7886 2500 www.panmure.com

College Hill

Melanie Toyne Sewell / Stefanie Bacher / Rebecca Caygill / Donia Al Saffar
Tel: +44 (0) 20 7457 2020
Email: e-therapeutics@collegehill.com

CommStrat Group (US)

Ted Agne
Tel: (+1) 781 631 3117
Email: edagne@comstratgroup.com

About ETS6103

ETS6103 is a controlled-release formulation of tramadol. An earlier small phase IIa study produced encouraging results when it compared ETS6103 with the established antidepressant amitriptyline in patients with major depressive disorder.

About e-Therapeutics

e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is focused in cancer and disorders of the nervous system.
e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on E-THERAPEUTICS PLC
06/14Suspended Woodford fund has sold around £100 million of assets
RE
02/28E-THERAPEUTICS PLC : annual earnings release
2018NOVO NORDISK A/S : begins R&D tie-up with AI biotech e-Therapeutics
AQ
2018E THERAPEUTICS : Danish drugs giant Novo Nordisk to use e-Therapeutics technolog..
AQ
2018E THERAPEUTICS : Research Collaboration Agreement with Novo Nordisk
PU
2018E THERAPEUTICS : and C4X Collaboration
PU
2018E THERAPEUTICS : Drug Discovery Innovation Programme Presentation
PU
2018E THERAPEUTICS : Interim Results for six months ended 31 July 2018
PU
2018E THERAPEUTICS : Notice of Interim Results
PU
2018E THERAPEUTICS : Director Shareholding
PU
More news
Financials (GBP)
Sales 2020 0,49 M
EBIT 2020 -3,63 M
Net income 2020 -2,66 M
Finance 2020 3,61 M
Yield 2020 -
P/E ratio 2020 -3,20x
P/E ratio 2021 -3,05x
EV / Sales2020 10,2x
EV / Sales2021 infx
Capitalization 8,61 M
Chart E-THERAPEUTICS PLC
Duration : Period :
e-Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends E-THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price
Last Close Price 3,20  GBp
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Raymond Barlow Chief Executive Officer & Director
Iain Gladstone Ross Non-Executive Chairman
Steven Medlicott Finance Director & Executive Director
Trevor Mervyn Jones Independent Non-Executive Director
Christine Helen Soden Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
E-THERAPEUTICS PLC-49.61%11
IQVIA HOLDINGS INC34.30%31 409
LONZA GROUP32.31%25 111
CELLTRION, INC.--.--%20 827
INCYTE CORPORATION26.17%17 419
EXACT SCIENCES CORPORATION84.37%15 001